Literature DB >> 3952805

Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog.

B Gridelli, L Scanlon, R Pellicci, R LaPointe, A DeWolf, H Seltman, W Diven, B Shaw, T Starzl, A Sanghvi.   

Abstract

The influence of assay method on single dose cyclosporine (CsA) pharmacokinetics was studied in nine dogs receiving either i.v. or oral CsA. Samples were drawn from hepatic, portal, and systemic veins at various times after the dose and CsA levels were determined by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Blood concentration-time data were analyzed by nonlinear least-squares regression, using two-compartment models. RIA/HPLC ratios for all samples were greater than one, and did not change significantly over time. The mean RIA/HPLC ratios for samples drawn from all three veins were higher after oral than i.v. doses of the drug (P less than 0.05). Area under the concentration-time curve (AUC) was higher and systemic clearance (CIs) lower than calculated on the basis of RIA results, regardless of the route of administration. AUC calculated for CsA metabolites (RIA-HPLC) was highest in the portal vein after an oral dose of CsA. Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively. The mean CsA metabolite index (CMI), when calculated for hepatic, portal, or systemic vein, was greater when the drug was administered orally. The mean hepatic extraction ratio (HER) of the parent drug and for CsA metabolites was approximately 23% in i.v. and p.o. studies. These results suggest that the gastrointestinal tract may play a role in the metabolism of CsA when the drug is administered orally. In addition, if CsA metabolites not measured by HPLC have either toxic or immunosuppressive properties, the RIA assay may be more useful for monitoring patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3952805      PMCID: PMC3000222          DOI: 10.1097/00007890-198603000-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients.

Authors:  G Burckart; T Starzl; L Williams; A Sanghvi; C Gartner; R Venkataramanan; B Zitelli; J Malatack; A Urbach; W Diven; R Ptachcinski; B Shaw; S Iwatsuki
Journal:  Transplant Proc       Date:  1985-02       Impact factor: 1.066

2.  Clinical Aspects of Cyclosporine Therapy: A Summation.

Authors:  T E Starzl
Journal:  Transplant Proc       Date:  1983-12       Impact factor: 1.066

Review 3.  Cyclosporin A--usefulness, risks and mechanism of action.

Authors:  S Britton; R Palacios
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

4.  The effects and side effects of cyclosporine: relationship to drug pharmacokinetics.

Authors:  P A Keown; C R Stiller; A L Laupacis; W Howson; R Coles; M Stawecki; J Koegler; G Carruthers; N McKenzie; N R Sinclair
Journal:  Transplant Proc       Date:  1982-12       Impact factor: 1.066

5.  Hepatic blood flow measurement III. Total hepatic blood flow measured by ICG clearance and electromagnetic flowmeters in a canine septic shock model.

Authors:  J L Nxumalo; M Teranaka; W G Schenk
Journal:  Ann Surg       Date:  1978-03       Impact factor: 12.969

6.  Liquid-chromatographic determination of cyclosporin A in blood and plasma.

Authors:  R J Sawchuk; L L Cartier
Journal:  Clin Chem       Date:  1981-08       Impact factor: 8.327

7.  Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients. Comparison of two assay methods.

Authors:  G C Yee; M S Kennedy; R Storb; E D Thomas
Journal:  Transplantation       Date:  1984-11       Impact factor: 4.939

8.  Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.

Authors:  J F Elliott; Y Lin; S B Mizel; R C Bleackley; D G Harnish; V Paetkau
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

  8 in total
  9 in total

1.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Cyclosporin metabolism by the gastrointestinal mucosa.

Authors:  J F Tjia; I R Webber; D J Back
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 3.  Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications.

Authors:  P O Gubbins; K E Bertch
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

4.  Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

Authors:  I R Webber; W H Peters; D J Back
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

5.  Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

Authors:  J M Tredger; J Grevel; N Naoumov; C M Steward; A A Niven; B Whiting; R Williams
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Evidence for pre-hepatic metabolism of oral cyclosporine in children.

Authors:  K Hoppu; O Koskimies; C Holmberg; E L Hirvisalo
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

7.  Chronopharmacokinetics of Cyclosporine A in the Wistar rat following oral administration.

Authors:  M F Malmary; K Kabbaj; C Labat; A Batalla; I Houti; S Moussamih; J Oustrin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

8.  The preparation and evaluation of a tablet dosage form of cyclosporine in dogs.

Authors:  H Y Abdallah; M Mayersohn
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

9.  Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine.

Authors:  S A Gruber; S Venkataram; D M Canafax; R J Cipolle; L Bowers; D Elsberry; M McGuiggan; P E Hynes; J A Ritz; F H Gould
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.